In recent years, special interest has been paid to the aminopeptidases localized on the plasma membrane of immune cells. These aminopeptidases are able to inactivate peptides, and most of them have a common structure which is called a type II integral membrane protein, e.g., aminopeptidase A (APA/BP-1/6C3; EC 3.4.11.7) (1, 2), cystine aminopeptidase (oxytocinase) (CAP; EC 3.4.11.3) (3, 4), neutral endopeptidase (NEP/CD10; EC 3.4.24.11) (5), aminopeptidase N (APN/CD13; EC 3.4.11.2) (6), and dipeptidyl peptidase IV (DPP IV/CD26; EC 3.4.14.5) (7) (8) (9) (10) . The structure of the type II integral membrane protein consists of a single hydrophobic N-terminal domain, a transmembrane region, and the C-terminal portion con taining a catalytic site.
One of these molecules, DPP IV can release N-terminal dipetides, preferentially cleaving prolyl or alanyl bonds (11, 12) . By virtue of its predominant localization in the brush border of small intestine and kidney proximal tubules, it was initially suggested that DPP IV participates in the metabolism and the uptake of proline-containing peptides in these tissues (13) . Recent studies have also revealed that DPP IV is a leukocyte differentiation antigen, CD26, which is expressed on a subpopulation of human T cells (14, 15) . DPP IV/CD26 transduces differentiation and activation signals in T cells (16) (17) (18) DPP IV functions as a membrane-bound peptidase on the cell surface as described above. On the other hand, DPP IV activity is also present in body fluids such as serum (24) and seminal plasma (25). The DPP IV activity in serum is found to be elevated in patients with hepatitis and hepatobiliary diseases, but decreased in patients with gastric cancer, pancreatic cancer, systemic lupus erythematosus, and rheumatoid arthritis (26-28).
Because of the hydrophobic domain which fixes the molecule to the membrane, it is necessary to use detergentcontaining solution to solubilize the entire membranebound DPP IV from the membrane.
We reasoned, therefore, that the deletion of the hydrophobic domain might be essential for the existence of DPP IV in serum. In this study, we describe the purification of DPP IV from human serum and its characterization, including its N-terminal amino acid sequence analysis. Protein Assay-Protein concentration was determined by measuring the absorbance of the sample solution at 280 nm or by use of a BCA Protein Assay Kit (Pierce, Rockford, IL, USA).
MATERIALS AND METHODS

Materials
Polyaerylamide
Gel Electrophoresis-SDS-1'A( was carried out using 7.5% polyacrylamide gels according to the method of Laemmli (30).
Determination of N-Terminal Amino Acid Sequence of DPP IV-Purified
DPP IV was electrophoresed on a 7.5% SDS-PAGE gel, electrotransferred to polyvinylidene difluoride (PVDF) membranes (Pro Blott; Applied Biosystems, Foster City, CA, USA), and stained with 0.1% Ponceau S. The areas corresponding to DPP IV band were cut off. The destained PVDF membranes thus obtained were subjected to an Applied Biosystems model 477A Protein Sequencer.
Preparation of Antibodies-To prepare antiserum against human membrane-bound kidney DPP IV, a peptide fragment consisting of 16 amino acid residues (MKTPWK-VLLGLLGAAA) from the N-terminus of kidney DPP IV was synthesized by the Fmoc-polyamide solid phase method. A Cys residue was added to the C-terminus of the peptide to allow coupling to keyhole lympet hemocyanin with maleimido-benzoyl-N-hydroxysuccinimide ester. A KBL: JW rabbit was immunized by subcutaneous injection of Freund's complete adjuvant containing 1.25 mg of conjugate. Booster injections of 1.25 mg of the conjugate were performed three times at 3-week intervals. Serum was collected 73 days after the first injection. Immunoglobulins in the anti-serum were purified as described previously (31).
Rat kidney DPP IV was purified and a rabbit IgG anti-rat kidney DPP IV antibody was raised as described before (32) .
A specific rabbit IgG anti-calf ADA antibody was raised as described before (33) .
Purification of Human Serum DPP IV-All purification steps were performed at 4°C.
Step 1. DEAE-Cellulose DE-52 column chromatography: Human serum (200 ml) was dialyzed against 10 mM TrisHCl buffer, pH 8.0 (buffer A). The dialyzate was centri fuged at 10,000 X g for 10 min to remove the insoluble materials. The supernatant was used in the subsequent steps. The supernatant was applied to a DEAE-Cellulose DE-52 column (2.5 x 40 cm) previously equilibrated with buffer A. The column was washed with the equilibration buffer, then developed with 2 liters of a linear gradient of NaCl (0-0.3 M), Fractions containing DPP IV activity were pooled and dialyzed against buffer A.
Step 2. DEAE-Cellulofine A800 column chromatography: The dialyzed fractions were rechromatographed on a second anion-exchange column (DEAE-Cellulofine A800, 2.5 x 35 cm) equilibrated with buffer A. The column was washed, then developed with 1 liter of a linear gradient of NaCl (0-0.2 M). The active fractions were pooled and concentrated using 10-kDa cut-off centrifugal concentra tors (Centriprep 10; Amicon, Beverly, MA, USA).
Step 3. Sephacryl S-300 HR column chromatography: The concentrated sample was applied to a Sephacryl 5-300 HR column (2.5 X 90 cm) equilibrated with buffer A con taining 0.1 M NaCl. The column was developed with the same buffer and the active fractions were pooled. The solution was adjusted to 40% saturation with ammonium sulfate.
Step 4. Butyl-Toyopearl S column chromatography: The solution was applied to a butyl-Toyopearl S column (1.5 x 7 cm) equilibrated with 40% ammonium sulfate-saturated buffer A. The column was washed with the same buffer, then the bound proteins were eluted with 200 ml of a linear gradient of ammonium sulfate, 40-0%. The active fractions were dialyzed against buffer A. This preparation was used in subsequent experiments.
Purification of Human Membrane-Bound Kidney DPP IV -An intact membrane-bound kidney DPP IV was purified as follows. All purification steps were performed at 4°C unless otherwise stated. Supernatants of the micro somes of human kidney were prepared as described before (34) . DPP IV was purified from the supernatant by passing it through a rabbit IgG anti-rat kidney DPP IV Sepharose 4B column (1.5 X 8 cm) equilibrated with buffer A containing 0.05% Triton X-100 and 0.15 M NaCl. After washing the column with the same buffer, the bound protein was eluted with 50 mM diethylamine-HC1 (pH 11.0) containing 0.05% Triton X-100 at room temperature. Immediately, the active fractions were pooled and dialyzed against buffer Western Blotting-Purified DPP IV was electrophoresed on a 7.5% SDS-PAGE gel and electrotransferred to PVDF membranes. After the electroblotting, the membranes were treated with rabbit IgG anti-rat kidney antibody (10 ,ug/ml) or rabbit IgG anti-peptide antibody (25,ug/ml). HRPO-conjugated Protein A was used as a second antibody. The enhanced chemiluminescence (ECL) system (Amersham) was used for detection. The membranes were subsequently exposed to Hyperfilm-3H autoradiography film and processed. 
RESULTS AND DISCUSSION
Purification of Human Serum DPP IV-Human serum DPP IV was isolated by sequential purification using ion exchange chromatography (DEAE-Cellulose DE-52 and DEAE-Cellulofine A-800), gel filtration on a Sephacryl S-300 HR column, and hydrophobic chromatography on a butyl-Toyopearl 650S column. The purification steps for DPP IV are summarized in Table I . Serum DPP IV was purified 14,400-fold with a 25% yield over serum. Its specific activity was 19.1,u mol/min/mg protein with GlyPro-pNA as the substrate. The purified enzyme migrated as a single band on SDS-PAGE under reducing conditions (Fig .  1) . The molecular mass of the enzyme was estimated to be 110 kDa, similar to that of the human membrane-bound kidney DPP IV. The purified enzyme also showed the same molecular weight band under non-reducing conditions (data not shown). We have previously reported that our anti-rat kidney DPP IV antibody recognizes a 60-kDa fragment of rat kidney DPP IV cut off at the 281st residue from the N-terminus (34) . DPP IVs from serum and kidney showed cross-reactivity to the anti-rat kidney DPP IV antibody in Western blotting, and their molecular sizes were identical (data not shown). Kidney DPP IV is a serine protease and an aminopep. tidase which can be inhibited by DFP (25) and diprotin-A (36), respectively. We examined the effects of DFP and diprotin-A on DPP IVs from kidney and serum. Both DPP IVs were inhibited by DFP and diprotin-A in the same manner. IDso of DFP for kidney and serum DPP IVs was 0.55 and 0.50 mM, respectively, and IDso of diprotin-A for kidney and serum DPP IVs was the same (20 MM). Therefore, we can confirm that serum DPP IV is a serine oroteinase.
N-Glycanase Treatment of DPP IVs-DPP IV is regularly present as a non-covalently linked homodimeric glyco protein, consisting of two N-glycosylated subunits of 110 kDa (8) . So we investigated the pattern of glycosylation of the membrane-bound and serum forms. As shown in Fig. 2 , the deglycosylated backbone of serum DPP IV is slightly smaller than that of kidney DPP IV. This result demon- a One unit (U) is defined as the amount of enzyme cleaving 1 ymol of Gly -Pro-pNA/min.
strates that there is a difference in the primary structure of the DPP IVs.
Comparison of the N-Terminal Amino Acid SequencesTo investigate the primary structure of DPP IVs, the N-terminal amino acid sequences of membrane-bound kidney and serum DPP IVs were determined and compared with the amino acid sequence predicted from the cDNA nucleotide sequence of human liver DPP IV (8) (Fig. 3) . The entire amino acid sequence of human kidney DPP IV including the transmembrane site has not yet been reported. However, we revealed that the N-terminal sequence of human kidney membrane-bound DPP IV was completely identical to the predicted structure. On the other hand, the N-terminal sequence of serum DPP IV was identified in a sequence starting at the 39th position, serine, from the N-terminus. These results suggest that membrane-bound DPP IV loses its transmembrane domain upon release into the serum.
To confirm the loss of the transmembrane domain, the cross-reactivity of serum DPP IV with an anti-peptide antibody against the N-terminus of kidney DPP IV was examined. A peptide fragment consisting of 16 amino acid residues (MKTPWKVLLGLLGAAA) from the N-terminus of kidney DPP IV was synthesized using the Fmoc polyamide solid-phase method, and a polyclonal antibody was raised in rabbit. Kidney membrane-bound DPP IV cross-reacted with the anti-peptide antibody, but serum DPP IV did not (Fig. 4) . This result supports the N-terminal amino acid sequence analysis of serum DPP IV as lackine the transmembrane domain.
Our previous studies have shown that APN and CAP in sera from pregnant women are differently processed derivatives of membrane-bound APN and CAP, respectively (37, 38) . Furthermore, our recent result indicates that APN in normal human serum is a differently processed derivative from the one in maternal serum (39) . DPP IV, like APN and CAP, is a type II integral membrane aminopeptidase. We can, therefore, propose with certainty that the type II integral membrane aminopeptidases can be released from the membrane to the blood circulation by differential limited proteolysis, though the mechanism of release remains unclear.
While this study was in progress, Duke-Uohan et at. reported that a novel form of DPP IV was found in human serum that was not a cleavage product of CD26/DPP IV (40) . Their DPP IV existed as a monomer of 175 kDa and the N-terminal sequences of its tryptic digest have no homology with CD26/DPP IV. They also reported finding a novel activated T cell antigen (DPPT-L), and that the 175-kDa DPP IV is similar to DPPT-L released from activated T cells (41) . We think the inconsistency between their findings and our data might have resulted from their missing the real serum DPP IV during their purification processes. Our conclusion indicates that serum DPP IV is a cleavage product of 110-kDa membrane-bound DPP IV. Furthermore, it seems that what Duke-Cohan et al. call 175-kDa DPP IV is quite different from real serum DPP IV Fig. 2 . N-Glycanase digestion of DPP IVs from kidney and serum. The proteins were incubated overnight at 37°C in the presence (+) or absence (-) of N-glycanase as described under "MATERIALS AND METHODS." The digested proteins were subjected to SDS-PAGE (7.5% gel), followed by Western blotting with a rabbit anti-rat kidney DPP IV antibody. Marker proteins used are f3-galactosidase (116 kDa), phosphorylase a (94 kDa), bovine serum albumin (68 kDa), and ovalbumin (45 kDa). DPP IV Binding to Adenosine Deaminase-Human ADA exists in three forms: a low molecular weight type 1 (ADA-S, 40 kDa); a high molecular weight type 1 (ADA-L, 280 kDa) ; and an intermediate molecular weight type 2 (ADA-2, 110 kDa) (42) . ADA-S predominates in almost all intracellular tissues and membranes, and is convertible to ADA-L, which is a complex of ADA-S (2 molecules) and DPP IV (1 molecule). On the other hand, ADA-2 is predom inantly found in the serum and its properties have not yet been clarified. As shown in Fig. 5A , serum DPP IV (lane 3), like kidney DPP IV (lane 5), could exist as a dimer in non-SDS-PAGE gel. Upon incubation withhhhhh ADA-S, the 220-kDa band of both serum and kidney DPP IVs disap peared and a new band with higher molecular weight appeared (lanes 2 and 4). Furthermore, in both serum and kidney DPP IVs, Western blotting using a rabbit IgG anti-ADA antibody showed the translocation of ADA from low molecular weight ADA (ADA-S) to the high molecular weight complex of DPP IV and ADA (ADA-L) (Fig. 5B) . These results suggest that ADA-S can associate with both serum and membrane-bound DPP IV. Recently, some groups have reported that ADA-S interacts with the membrane form of DPP IV (21, 43), but Duke-Cohan et al. reported that DPP IV in human serum did not bind to ADA-S (40) . From the point of view outlined above, we may question the sample which Duke-Cohan et al. used. Our result then suggests that DPP IV dose not need to be fixed on the plasma membrane in order to bind to ADA.
At present, we do not know the mechanism of the release from the membrane to serum, but it is worthwhile to clarify it and to investigate the correlation of serum DPP IV with immune status.
